Pharma.Aero established the LMAP to engage directly with manufacturers in the life sciences field, providing first-line advice on Pharma.Aero’s activities and projects, and enhancing cross-industry initiatives with valuable content and insights. As part of its initiatives, the global collaborative platform is conducting an innovative study focusing on the specific logistics requirements of Advanced Therapy Medicinal Products, including Radioligand Therapy.
As a clinical-stage radiopharmaceutical company, ARTBIO is redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company’s AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.
ARTBIO is deeply rooted in a long-standing scientific legacy of pioneering work in radiation therapy, originating from groundbreaking research conducted at the University of Oslo and Norway’s Radium Hospital. This renowned research hub, with a lineage tracing back to Marie Curie, has been instrumental in advancing the field of radiology.
ARTBIO’s scientific founders, Roy Larsen and Øyvind Bruland, have been pivotal figures in this legacy. They invented Xofigo, the first-ever metabolically targeted alpha therapy, which was later acquired by Bayer through the company Algeta. Building on this legacy, Larsen and Bruland, in collaboration with the F-Prime team and Radforsk, laid the foundation of ARTBIO in 2021, continuing their commitment to revolutionizing cancer treatment.
Pharma.Aero’s Life Science Manufacturers Advisory Platform (LMAP) provides life science manufacturers with a voice in Pharma.Aero’s projects and activities, fostering collaboration and innovation across the industry.